West Pharmaceutical Services, Inc.
WST
Classifica tra le azioni
#880
West Pharmaceutical Services, Inc. (WST) specializes in the development,... West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
Prezzo delle azioni
$389.10
Ultima sincronizzazione: 2026-10-20
Capitalizzazione di mercato
$27.38B
Variazione (1 giorno)
1.30%
Variazione (1 anno)
39.27%
Paese
US
Scambia West Pharmaceutical Services, Inc. (WST)
Categoria
Healthcare
Ricavi di West Pharmaceutical Services, Inc. (WST)
Ricavi nel Jun 2026 TTM: $3.33B
Secondo gli ultimi rapporti finanziari di West Pharmaceutical Services, Inc., i ricavi attuali dell'azienda (TTM) sono pari a $3.33B. Nel 2024, l'azienda ha registrato ricavi di $2.89B una diminuzione rispetto a i ricavi dell'anno 2023, che erano pari a $2.95B. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per West Pharmaceutical Services, Inc. da 2000 a 2026
Ricavi alla fine di ogni anno
| Anno | Ricavi | Cambia |
|---|---|---|
| 2026 (TTM) | $3.33B | 8.21% |
| 2025 | $3.07B | 6.27% |
| 2024 | $2.89B | -1.98% |
| 2023 | $2.95B | 2.27% |
| 2022 | $2.89B | 1.94% |
| 2021 | $2.83B | 31.86% |
| 2020 | $2.15B | 16.44% |
| 2019 | $1.84B | 7.31% |
| 2018 | $1.72B | 7.36% |
| 2017 | $1.60B | 6.04% |
| 2016 | $1.51B | 7.95% |
| 2015 | $1.40B | -1.67% |
| 2014 | $1.42B | 3.91% |
| 2013 | $1.37B | 8.04% |
| 2012 | $1.27B | 6.19% |
| 2011 | $1.19B | 7.96% |
| 2010 | $1.10B | 4.64% |
| 2009 | $1.06B | 0.44% |
| 2008 | $1.05B | 3.04% |
| 2007 | $1.02B | 11.69% |
| 2006 | $913.30M | 30.53% |
| 2005 | $699.70M | 29.19% |
| 2004 | $541.60M | 10.37% |
| 2003 | $490.70M | 16.92% |
| 2002 | $419.70M | 5.74% |
| 2001 | $396.90M | -7.72% |
| 2000 | $430.10M | 0.00% |
Ricavi di aziende simili o concorrenti
| Azienda | Ricavi | Differenza nei ricavi | Il paese |
|---|---|---|---|
| $11.03B | 231.71% |
US
|
|
| $34.74B | 944.24% |
FR
|
|
| - | - |
JP
|
|
| $20.84B | 526.45% |
US
|
|
| - | - |
CH
|
